Levothyroxine formulations [Design Issues]

posted by drcampos  – Brazil, 2007-04-24 06:46 (6652 d 16:52 ago) – Posting: # 689
Views: 10,265

Dear All,

I would like to evaluate the disposition of lower dosages of levothyroxine formulations, i.e 12,5 mg and 37.5 mg (new formulations). Considering the FDA Guidance it is necessary a dose of 600 mcg for avoinding baseline effect. So, the problem is the dose (48 tablets x 12.5 mcg = 600 mcg). Does someone have experience with these studies?

Regards,

Daniel

Complete thread:

UA Flag
Activity
 Admin contact
23,430 posts in 4,931 threads, 1,674 registered users;
45 visitors (0 registered, 45 guests [including 7 identified bots]).
Forum time: 23:38 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5